Novartis Navigates Metabolic Syndrome, Finds Link To Liver Disease

Novartis is using the screening process for the NAVIGATOR study of Diovan and Starlix to connect metabolic syndrome with markers for liver disease, according to data presented at the American Heart Association annual meeting Nov. 16 in Dallas